MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Intellipharmaceutics International, Inc. (IPCI) Is “One To Watch” 1 comment
    Apr 3, 2013 5:43 PM | about stocks: IPCI

    Pharmaceutical company Intellipharmaceutics International is poised for a potential landmark year.

    Specializing in the research, development, and commercialization of controlled-release and targeted pharmaceutical products, Intellipharmaceutics waits at the ready with product candidates that have helped the company garner "Buy" ratings from four different analysts.

    Analysts from three firms, including Ladenburg Thalmann and Maxim Group, have projected a $7 price target for Intellipharmaceutics. Jason Kolbert of Maxim Group foresees that Intellipharmaceutics can become a pioneer in launching generic long-acting versions of existing therapeutics - also cashing in on the growing concern over prescription drug abuse and recent legislative efforts to curtail that problem through the development of abuse-deterrent drugs.

    Rexista is an Intellipharmaceutics drug delivery platform that has been created to work with opioids to prevent abuse of them by injection, inhalation, or oral ingestion. Users commonly abuse oxycodone, for example, by pairing it with alcohol - a combination that can be lethal. Rexista provides an answer to this abuse problem by keeping the entire dose of oxycodone or other opioid from being released when alcohol is present in the system - thus negating the effects the abuser was hoping to achieve.

    In February, Rep. William Keating, D-Mass., introduced "H.R. 486: Stop Tampering of Prescription Pills Act of 2013," a bill aimed at incentivizing the development of abuse-deterrent drugs. The FDA has additionally released recent statements about its concern over prescription opioid abuse. As the nation seeks solutions for this ever-growing problem, Intellipharmaceutics is poised to capitalize.

    In addition to Rexista, Intellipharmaceutics has other pipeline products in line that promise lucrative earnings. The company's Focalin XR, a time-release drug used in the treatment of ADHD, is awaiting FDA clearance and has the potential for first-to-file status. The market for Focalin XR is projected to be more than $614 million in the United States alone.

    If analysts' estimates are correct, Intellipharmaceutics is a company that should be watched very closely. For more information on the company, visit www.intellipharmaceutics.com.

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: IPCI
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • filoblack
    , contributor
    Comments (23) | Send Message
    This year will be a breakout year for IPCI. $7.00 price target is modest. The weather has built for a 10 bagger.
    5 Apr 2013, 06:40 AM Reply Like
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.